Author

A. Miro Canturri

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 3 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

J. Pachon· 3 shared R. Ayerbe Algaba· 3 shared Y. Smani· 3 shared M. E. Jimenez-Mejias· 2 shared A. Ganez Zapater· 1 shared A. Vila-Dominguez· 1 shared C. Cannata· 1 shared D. Cianferoni· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

J. Pachon

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

The BRD4S-LOXL2-MED1 interaction at the forefront of cell cycle transcriptional control in triple-negative breast cancer

L. Pascual-Reguant, T. V. Tian, D. Datta, D. Cianferoni, S. Kourtis, A. Ganez Zapater, C. Cannata, Q. Serra Camprubi, L. Espinar, M. Guirola, J. Querol, A. Miro Canturri, J. Arribas, L. Serrano, S. Peiro, S. Sdelci

This study shows that inhibiting LOXL2 and BRD4 together reduces triple-negative breast cancer proliferation by disrupting the BRD4S-LOXL2-MED1 interaction that controls cell cycle gene expression.

bioRxiv · May 27, 2022 · PreprintCancer Biology

Repurposing of the tamoxifen metabolites to treat methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecalis infections

A. Miro Canturri, A. Vila-Dominguez, R. Ayerbe Algaba, J. Pachon, M. E. Jimenez-Mejias, Y. Smani

This paper shows that tamoxifen metabolites have antibacterial effects against MRSE and vancomycin-resistant E. faecalis, with activity linked to increased membrane permeability.

bioRxiv · May 20, 2021Microbiology

Efficacy of lysophosphatidylcholine as direct treatment in combination with colistin against Acinetobacter baumannii in murine severe infections models

A. Miro Canturri, R. Ayerbe Algaba, M. E. Jimenez-Mejias, J. Pachon, Y. Smani

This study evaluates the efficacy of lysophosphatidylcholine combined with colistin in treating Acinetobacter baumannii infections in mice, showing improved bacterial clearance and survival.

bioRxiv · Dec 2, 2020Microbiology

Tamoxifen repurposing to combat infections by multidrug-resistant Gram-negative bacilli

A. Miro Canturri, R. Ayerbe Algaba, R. del Toro, J. Pachon, Y. Smani

This paper shows tamoxifen reduces inflammation and bacterial load in MDR-GNB infections and has antimicrobial activity via its metabolites.

bioRxiv · Mar 30, 2020Microbiology